1
|
Walker E, Srienc A, Lew D, Guniganti R, Lanzino G, Brinjikji W, Hayakawa M, Samaniego EA, Derdeyn CP, Du R, Lai R, Sheehan JP, Starke RM, Abla A, Abdelsalam A, Gross B, Albuquerque F, Lawton MT, Kim LJ, Levitt M, Amin-Hanjani S, Alaraj A, Winkler E, Fox WC, Polifka A, Hall S, Bulters D, Durnford A, Satomi J, Tada Y, van Dijk JMC, Potgieser ARE, Chen CJ, Becerril-Gaitan A, Osbun JW, Zipfel GJ. Dural arteriovenous fistulas are not observed to convert to a higher grade after partial embolization. Neurosurg Focus 2024; 56:E8. [PMID: 38428013 DOI: 10.3171/2024.1.focus23745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Accepted: 01/02/2024] [Indexed: 03/03/2024]
Abstract
OBJECTIVE Borden-Shucart type I dural arteriovenous fistulas (dAVFs) lack cortical venous drainage and occasionally necessitate intervention depending on patient symptoms. Conversion is the rare transformation of a low-grade dAVF to a higher grade. Factors associated with increased risk of dAVF conversion to a higher grade are poorly understood. The authors hypothesized that partial treatment of type I dAVFs is an independent risk factor for conversion. METHODS The multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research database was used to perform a retrospective analysis of all patients with type I dAVFs. RESULTS Three hundred fifty-eight (33.2%) of 1077 patients had type I dAVFs. Of those 358 patients, 206 received endovascular treatment and 131 were not treated. Two (2.2%) of 91 patients receiving partial endovascular treatment for a low-grade dAVF experienced conversion to a higher grade, 2 (1.5%) of 131 who were not treated experienced conversion, and none (0%) of 115 patients who received complete endovascular treatment experienced dAVF conversion. The majority of converted dAVFs localized to the transverse-sigmoid sinus and all received embolization as part of their treatment. CONCLUSIONS Partial treatment of type I dAVFs does not appear to be significantly associated with conversion to a higher grade.
Collapse
Affiliation(s)
- Erin Walker
- 1University of South Carolina School of Medicine, Greenville, South Carolina
- 2Department of Neurological Surgery, Washington University in St. Louis, Missouri
| | - Anja Srienc
- 2Department of Neurological Surgery, Washington University in St. Louis, Missouri
| | - Daphne Lew
- 3Center for Biostatistics and Data Science, Washington University in St. Louis School of Medicine, St. Louis, Missouri
| | - Ridhima Guniganti
- 2Department of Neurological Surgery, Washington University in St. Louis, Missouri
| | | | | | - Minako Hayakawa
- 5Department of Radiology and Interventional Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Edgar A Samaniego
- 6Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Colin P Derdeyn
- 5Department of Radiology and Interventional Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Rose Du
- 7Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - Rosalind Lai
- 7Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - Jason P Sheehan
- 8Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
| | - Robert M Starke
- 9Neurosurgery Department, University of Miami Miller School of Medicine, Miami, Florida
| | - Adib Abla
- 9Neurosurgery Department, University of Miami Miller School of Medicine, Miami, Florida
- 15Department of Neurosurgery, University of California, San Francisco, California
| | - Ahmed Abdelsalam
- 9Neurosurgery Department, University of Miami Miller School of Medicine, Miami, Florida
| | - Bradley Gross
- 10Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Felipe Albuquerque
- 11Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona
| | - Michael T Lawton
- 11Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona
| | - Louis J Kim
- 12Department of Neurosurgery, University of Washington, Seattle, Washington
| | - Michael Levitt
- 12Department of Neurosurgery, University of Washington, Seattle, Washington
| | - Sepideh Amin-Hanjani
- 13Neurosurgery Department, University Hospitals/Case Western Reserve University, Cleveland, Ohio
- 14Department of Neurosurgery, University of Illinois College of Medicine at Chicago, Illinois
| | - Ali Alaraj
- 14Department of Neurosurgery, University of Illinois College of Medicine at Chicago, Illinois
| | - Ethan Winkler
- 15Department of Neurosurgery, University of California, San Francisco, California
| | - W Christopher Fox
- 16Department of Neurosurgery, University of Florida, Gainesville, Florida
| | - Adam Polifka
- 17Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida
| | - Samuel Hall
- 18Wessex Neurological Centre, Southampton General Hospital, Southampton, United Kingdom
| | - Diederik Bulters
- 18Wessex Neurological Centre, Southampton General Hospital, Southampton, United Kingdom
| | - Andrew Durnford
- 18Wessex Neurological Centre, Southampton General Hospital, Southampton, United Kingdom
| | | | - Yoshiteru Tada
- 19Department of Neurosurgery, University of Tokushima, Japan
| | - J Marc C van Dijk
- 20Department of Neurosurgery, University of Groningen, The Netherlands; and
| | | | - Ching-Jen Chen
- 21Department of Neurosurgery, University of Texas-Houston, Texas
| | | | - Joshua W Osbun
- 2Department of Neurological Surgery, Washington University in St. Louis, Missouri
| | - Gregory J Zipfel
- 2Department of Neurological Surgery, Washington University in St. Louis, Missouri
| |
Collapse
|
2
|
El Naamani K, Chen CJ, Jabre R, Saad H, Grossberg JA, Dmytriw AA, Patel AB, Khorasanizadeh M, Ogilvy CS, Thomas A, Monteiro A, Siddiqui A, Cortez GM, Hanel RA, Porto G, Spiotta AM, Piscopo AJ, Hasan DM, Ghorbani M, Weinberg J, Nimjee SM, Bekelis K, Salem MM, Burkhardt JK, Zetchi A, Matouk C, Howard BM, Lai R, Du R, Abbas R, Sioutas GS, Amllay A, Munoz A, Atallah E, Herial NA, Tjoumakaris SI, Gooch MR, Rosenwasser RH, Jabbour P. Direct Versus Indirect Revascularization for Moyamoya: a Large Multicenter Study. J Neurol Neurosurg Psychiatry 2024; 95:256-263. [PMID: 37673641 DOI: 10.1136/jnnp-2022-329176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 08/22/2023] [Indexed: 09/08/2023]
Abstract
BACKGROUND Moyamoya is a chronic occlusive cerebrovascular disease of unknown etiology causing neovascularization of the lenticulostriate collaterals at the base of the brain. Although revascularization surgery is the most effective treatment for moyamoya, there is still no consensus on the best surgical treatment modality as different studies provide different outcomes. OBJECTIVE In this large case series, we compare the outcomes of direct (DR) and indirect revascularisation (IR) and compare our results to the literature in order to reflect on the best revascularization modality for moyamoya. METHODS We conducted a multicenter retrospective study in accordance with the Strengthening the Reporting of Observational studies in Epidemiology guidelines of moyamoya affected hemispheres treated with DR and IR surgeries across 13 academic institutions predominantly in North America. All patients who underwent surgical revascularization of their moyamoya-affected hemispheres were included in the study. The primary outcome of the study was the rate of symptomatic strokes. RESULTS The rates of symptomatic strokes across 515 disease-affected hemispheres were comparable between the two cohorts (11.6% in the DR cohort vs 9.6% in the IR cohort, OR 1.238 (95% CI 0.651 to 2.354), p=0.514). The rate of total perioperative strokes was slightly higher in the DR cohort (6.1% for DR vs 2.0% for IR, OR 3.129 (95% CI 0.991 to 9.875), p=0.052). The rate of total follow-up strokes was slightly higher in the IR cohort (8.1% vs 6.6%, OR 0.799 (95% CI 0.374 to 1.709) p=0.563). CONCLUSION Since both modalities showed comparable rates of overall total strokes, both modalities of revascularization can be performed depending on the patient's risk assessment.
Collapse
Affiliation(s)
- Kareem El Naamani
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Ching-Jen Chen
- Neurosurgery, The University of Texas Health Science Center, Houston, Texas, USA
| | - Roland Jabre
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Hassan Saad
- Neurosurgery, Emory University, Atlanta, Georgia, USA
| | | | - Adam A Dmytriw
- Neuroradiology and Neurointervention Service, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Department of Medical Imaging, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada
| | - Aman B Patel
- Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA
| | | | | | - Ajith Thomas
- Neurosurgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Andre Monteiro
- Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | - Adnan Siddiqui
- Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | - Gustavo M Cortez
- Neurosurgery, Baptist Medical Center Downtown, Jacksonville, Florida, USA
| | - Ricardo A Hanel
- Neurosurgery, Baptist Medical Center Downtown, Jacksonville, Florida, USA
| | - Guilherme Porto
- Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Alejandro M Spiotta
- Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Anthony J Piscopo
- Neurosurgery, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| | - David M Hasan
- Neurosurgery, Duke University, Durham, North Carolina, USA
| | - Mohammad Ghorbani
- Neurosurgery, Division of Vascular and Endovascular Neurosurgery, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)
| | - Joshua Weinberg
- Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Shahid M Nimjee
- Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Kimon Bekelis
- Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
| | - Mohamed M Salem
- Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jan-Karl Burkhardt
- Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Akli Zetchi
- Neurosurgery, Yale University, New Haven, Connecticut, USA
| | - Charles Matouk
- Neurosurgery, Yale University, New Haven, Connecticut, USA
| | - Brian M Howard
- Neurological Surgery, Emory University, Atlanta, Georgia, USA
| | - Rosalind Lai
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Rose Du
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Rawad Abbas
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Georgios S Sioutas
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Abdelaziz Amllay
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Alfredo Munoz
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Elias Atallah
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Nabeel A Herial
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | | | - Michael Reid Gooch
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Robert H Rosenwasser
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Pascal Jabbour
- Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| |
Collapse
|
3
|
Walker E, Srienc AI, Guniganti RR, Brinjikji W, Chen CJ, Abecassis IJ, Levitt MR, Durnford A, Polifka AJ, Derdeyn CP, Samaniego EA, Kwasnicki AM, Alaraj A, Potgieser AR, Sur S, Tada Y, Winkler EA, Lai R, Du R, Abla AA, Satomi J, Starke RM, Van Dijk MC, Amin-Hanjani S, Hayakawa M, Gross BA, Fox WC, Butlers D, Kim LJ, Sheehan JP, Lanzino G, Osbun JW, Zipfel GJ. 483 Partial Treatment as a Risk Factor in Up-Conversion of Type 1 dAVFs. Neurosurgery 2023. [DOI: 10.1227/neu.0000000000002375_483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
|
4
|
Durnford AJ, Akarca D, Culliford D, Millar J, Guniganti R, Giordan E, Brinjikji W, Chen CJ, Abecassis IJ, Levitt M, Polifka AJ, Derdeyn CP, Samaniego EA, Kwasnicki A, Alaraj A, Potgieser ARE, Chen S, Tada Y, Phelps R, Abla A, Satomi J, Starke RM, van Dijk JMC, Amin-Hanjani S, Hayakawa M, Gross B, Fox WC, Kim L, Sheehan J, Lanzino G, Kansagra AP, Du R, Lai R, Zipfel GJ, Bulters DO. Risk of Early Versus Later Rebleeding From Dural Arteriovenous Fistulas With Cortical Venous Drainage. Stroke 2022; 53:2340-2345. [PMID: 35420453 PMCID: PMC9232241 DOI: 10.1161/strokeaha.121.036450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Cranial dural arteriovenous fistulas with cortical venous drainage are rare lesions that can present with hemorrhage. A high rate of rebleeding in the early period following hemorrhage has been reported, but published long-term rates are much lower. No study has examined how risk of rebleeding changes over time. Our objective was to quantify the relative incidence of rebleeding in the early and later periods following hemorrhage. METHODS Patients with dural arteriovenous fistula and cortical venous drainage presenting with hemorrhage were identified from the multinational CONDOR (Consortium for Dural Fistula Outcomes Research) database. Natural history follow-up was defined as time from hemorrhage to first treatment, rebleed, or last follow-up. Rebleeding in the first 2 weeks and first year were compared using incidence rate ratio and difference. RESULTS Of 1077 patients, 250 met the inclusion criteria and had 95 cumulative person-years natural history follow-up. The overall annualized rebleed rate was 7.3% (95% CI, 3.2-14.5). The incidence rate of rebleeding in the first 2 weeks was 0.0011 per person-day; an early rebleed risk of 1.6% in the first 14 days (95% CI, 0.3-5.1). For the remainder of the first year, the incidence rate was 0.00015 per person-day; a rebleed rate of 5.3% (CI, 1.7-12.4) over 1 year. The incidence rate ratio was 7.3 (95% CI, 1.4-37.7; P, 0.026). CONCLUSIONS The risk of rebleeding of a dural arteriovenous fistula with cortical venous drainage presenting with hemorrhage is increased in the first 2 weeks justifying early treatment. However, the magnitude of this increase may be considerably lower than previously thought. Treatment within 5 days was associated with a low rate of rebleeding and appears an appropriate timeframe.
Collapse
Affiliation(s)
- Andrew J Durnford
- Wessex Neurological Center (A.J.D., D.A., J.M.), University Hospital Southampton, United Kingdom
| | - Danyal Akarca
- MRC Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom (D.A.)
| | - David Culliford
- University of Southampton (D.C.), University Hospital Southampton, United Kingdom
| | - John Millar
- Wessex Neurological Center (A.J.D., D.A., J.M.), University Hospital Southampton, United Kingdom
| | - Ridhima Guniganti
- Department of Neurological Surgery, Washington University, St. Louis, MO (R.G., G.J.Z.)
| | - Enrico Giordan
- Department of Neurological Surgery (E.G., W.B., G.L.), Mayo Clinic, Rochester, MN.,Department of Radiology (E.G., W.B., G.L.), Mayo Clinic, Rochester, MN
| | - Waleed Brinjikji
- Department of Neurological Surgery (E.G., W.B., G.L.), Mayo Clinic, Rochester, MN.,Department of Radiology (E.G., W.B., G.L.), Mayo Clinic, Rochester, MN
| | - Ching-Jen Chen
- Department of Neurological Surgery, University of Virginia, Charlottesville (C.-J.C., J.S.)
| | - Isaac Josh Abecassis
- Department of Neurological Surgery (I.J.A., M.L., L.K.), University of Washington, Seattle
| | - Michael Levitt
- Department of Neurological Surgery (I.J.A., M.L., L.K.), University of Washington, Seattle.,Stroke and Applied Neuroscience Center (M.L., L.K.), University of Washington, Seattle
| | - Adam J Polifka
- Department of Neurological Surgery, University of Florida, Gainesville (A.J.P., W.C.F.)
| | - Colin P Derdeyn
- Department of Neurology (C.P.D., E.A.S., M.H.), University of Iowa, Iowa City.,Department of Radiology (C.P.D., E.A.S., M.H.), University of Iowa, Iowa City
| | - Edgar A Samaniego
- Department of Neurology (C.P.D., E.A.S., M.H.), University of Iowa, Iowa City.,Department of Radiology (C.P.D., E.A.S., M.H.), University of Iowa, Iowa City
| | - Amanda Kwasnicki
- Department of Neurological Surgery, University of Illinois at Chicago (A.K., A.A., S.A.-H.)
| | - Ali Alaraj
- Department of Neurological Surgery, University of Illinois at Chicago (A.K., A.A., S.A.-H.).,Department of Neurological Surgery, University of Pittsburgh, PA (A.A., B.G.)
| | - Adriaan R E Potgieser
- Department of Neurological Surgery, University Medical Center Groningen, Netherlands (A.R.E.P., J.M.C.v.D.)
| | - Stephanie Chen
- Department of Neurological Surgery, University of Miami, FL (S.C., R.M.S.)
| | - Yoshiteru Tada
- Department of Neurosurgery, Institute of Biomedical Biosciences, Tokushima University Graduate School, Japan (Y.T., J.S.)
| | - Ryan Phelps
- Weill Institute for Neurosciences, Department of Neurosurgery, University of California San Francisco (R.P.)
| | | | - Junichiro Satomi
- Department of Neurological Surgery, University of Virginia, Charlottesville (C.-J.C., J.S.).,Department of Neurosurgery, Institute of Biomedical Biosciences, Tokushima University Graduate School, Japan (Y.T., J.S.)
| | - Robert M Starke
- Department of Neurological Surgery, University of Miami, FL (S.C., R.M.S.)
| | - J Marc C van Dijk
- Department of Neurological Surgery, University Medical Center Groningen, Netherlands (A.R.E.P., J.M.C.v.D.)
| | - Sepideh Amin-Hanjani
- Department of Neurological Surgery, University of Illinois at Chicago (A.K., A.A., S.A.-H.)
| | - Minako Hayakawa
- Department of Neurology (C.P.D., E.A.S., M.H.), University of Iowa, Iowa City.,Department of Radiology (C.P.D., E.A.S., M.H.), University of Iowa, Iowa City
| | - Bradley Gross
- Department of Neurological Surgery, University of Pittsburgh, PA (A.A., B.G.)
| | - W Christopher Fox
- Department of Neurological Surgery, University of Florida, Gainesville (A.J.P., W.C.F.)
| | - Louis Kim
- Department of Neurological Surgery (I.J.A., M.L., L.K.), University of Washington, Seattle.,Stroke and Applied Neuroscience Center (M.L., L.K.), University of Washington, Seattle
| | | | - Giuseppe Lanzino
- Wessex Neurological Center (A.J.D., D.A., J.M.), University Hospital Southampton, United Kingdom.,Department of Radiology (E.G., W.B., G.L.), Mayo Clinic, Rochester, MN
| | - Akash P Kansagra
- Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO (A.P.K.)
| | - Rose Du
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA (R.D., R.L.)
| | - Rosalind Lai
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA (R.D., R.L.)
| | - Gregory J Zipfel
- Department of Neurological Surgery, Washington University, St. Louis, MO (R.G., G.J.Z.)
| | | | | |
Collapse
|
5
|
Teo K, Cheow Y, Zhang S, Shi J, Lai R, Lim S, Toh W. Exosomes/EVs: MSC-SEVS ALLEVIATE LOCAL AND SYSTEMIC INFLAMMATION TO PROMOTE JOINT REPAIR IN OSTEOARTHRITIS. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00252-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Jiang Y, Teo K, Zhang S, Shi J, Lai R, Lim S, Toh W. Exosomes/EVs: MSC EXOSOMES ALLEVIATE OSTEOARTHRITIS THROUGH COMPLEMENT INHIBITION. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00251-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Chen CJ, Buell TJ, Ding D, Guniganti R, Kansagra AP, Lanzino G, Brinjikji W, Kim L, Levitt MR, Abecassis IJ, Bulters D, Durnford A, Fox WC, Polifka AJ, Gross BA, Hayakawa M, Derdeyn CP, Samaniego EA, Amin-Hanjani S, Alaraj A, Kwasnicki A, van Dijk JMC, Potgieser ARE, Starke RM, Chen S, Satomi J, Tada Y, Abla A, Phelps RRL, Du R, Lai R, Zipfel GJ, Sheehan JP. Observation Versus Intervention for Low-Grade Intracranial Dural Arteriovenous Fistulas. Neurosurgery 2021; 88:1111-1120. [PMID: 33582776 DOI: 10.1093/neuros/nyab024] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 12/14/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Low-grade intracranial dural arteriovenous fistulas (dAVF) have a benign natural history in the majority of cases. The benefit from treatment of these lesions is controversial. OBJECTIVE To compare the outcomes of observation versus intervention for low-grade dAVFs. METHODS We retrospectively reviewed dAVF patients from institutions participating in the CONsortium for Dural arteriovenous fistula Outcomes Research (CONDOR). Patients with low-grade (Borden type I) dAVFs were included and categorized into intervention or observation cohorts. The intervention and observation cohorts were matched in a 1:1 ratio using propensity scores. Primary outcome was modified Rankin Scale (mRS) at final follow-up. Secondary outcomes were excellent (mRS 0-1) and good (mRS 0-2) outcomes, symptomatic improvement, mortality, and obliteration at final follow-up. RESULTS The intervention and observation cohorts comprised 230 and 125 patients, respectively. We found no differences in primary or secondary outcomes between the 2 unmatched cohorts at last follow-up (mean duration 36 mo), except obliteration rate was higher in the intervention cohort (78.5% vs 24.1%, P < .001). The matched intervention and observation cohorts each comprised 78 patients. We also found no differences in primary or secondary outcomes between the matched cohorts except obliteration was also more likely in the matched intervention cohort (P < .001). Procedural complication rates in the unmatched and matched intervention cohorts were 15.4% and 19.2%, respectively. CONCLUSION Intervention for low-grade intracranial dAVFs achieves superior obliteration rates compared to conservative management, but it fails to improve neurological or functional outcomes. Our findings do not support the routine treatment of low-grade dAVFs.
Collapse
Affiliation(s)
- Ching-Jen Chen
- Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia, USA
| | - Thomas J Buell
- Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia, USA
| | - Dale Ding
- Department of Neurosurgery, University of Louisville, Louisville, Kentucky, USA
| | - Ridhima Guniganti
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Akash P Kansagra
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.,Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.,Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Giuseppe Lanzino
- Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
| | - Waleed Brinjikji
- Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
| | - Louis Kim
- Department of Neurosurgery, University of Washington, Seattle, Washington, USA
| | - Michael R Levitt
- Department of Neurosurgery, University of Washington, Seattle, Washington, USA
| | | | - Diederik Bulters
- Department of Neurosurgery, University of Southampton, Southampton, United Kingdom
| | - Andrew Durnford
- Department of Neurosurgery, University of Southampton, Southampton, United Kingdom
| | - W Christopher Fox
- Department of Neurosurgery, University of Florida, Gainesville, Florida, USA
| | - Adam J Polifka
- Department of Neurosurgery, University of Florida, Gainesville, Florida, USA
| | - Bradley A Gross
- Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Minako Hayakawa
- Department of Radiology, University of Iowa, Iowa City, Iowa, USA
| | - Colin P Derdeyn
- Department of Radiology, University of Iowa, Iowa City, Iowa, USA
| | | | | | - Ali Alaraj
- Department of Neurosurgery, University of Illinois, Chicago, Illinois, USA
| | - Amanda Kwasnicki
- Department of Neurosurgery, University of Illinois, Chicago, Illinois, USA
| | - J Marc C van Dijk
- Department of Neurosurgery, University of Groningen, Groningen, the Netherlands
| | | | - Robert M Starke
- Department of Neurosurgery, University of Miami, Miami, Florida, USA.,Department of Radiology, University of Miami, Miami, Florida, USA
| | - Stephanie Chen
- Department of Neurosurgery, University of Miami, Miami, Florida, USA
| | - Junichiro Satomi
- Department of Neurosurgery, Tokushima University, Tokushima, Japan
| | - Yoshiteru Tada
- Department of Neurosurgery, Tokushima University, Tokushima, Japan
| | - Adib Abla
- Department of Neurosurgery, University of California, San Francisco, San Francisco, California, USA
| | - Ryan R L Phelps
- Department of Neurosurgery, University of California, San Francisco, San Francisco, California, USA
| | - Rose Du
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Rosalind Lai
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Gregory J Zipfel
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Jason P Sheehan
- Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia, USA
| | | |
Collapse
|
8
|
Peng SHT, Wong B, Chen W, Lai R, Canterbury LA. Extracutaneous involvement of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis and refractory to intensive chemotherapy. J Hematop 2021. [DOI: 10.1007/s12308-021-00455-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
9
|
Toh W, Zhang S, Wong K, Ren X, Lai R, Lim S, Hui J. MSC exosomes promote osteochondral repair in a translational porcine model. Cytotherapy 2021. [DOI: 10.1016/s1465324921004540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Chuah S, Yong C, Chew J, Cheow Y, Teo K, Zhang S, Lai R, Wong R, Lim A, Lim S, Tohu W. Mesenchymal stromal cell-derived small extracellular vesicles promote angio-osteogenesis and modulate macrophage polarization to enhance bone regeneration. Cytotherapy 2021. [DOI: 10.1016/s1465324921004473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Teo K, Zhang S, Chuah S, Lai R, Lim S, Toh W. Mesenchymal stromal cell-derived small extracellular vesicles promote osteoarthritic joint repair and pain recovery through immunomodulation. Cytotherapy 2021. [DOI: 10.1016/s1465324921004515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Li X, Xing L, Lai R, Yuan C, Humbert P. Literature mapping: association of microscopic skin microflora and biomarkers with macroscopic skin health. Clin Exp Dermatol 2020; 46:21-27. [PMID: 32786033 PMCID: PMC7754415 DOI: 10.1111/ced.14353] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 03/09/2020] [Accepted: 05/27/2020] [Indexed: 10/27/2022]
Abstract
Associations between skin microbes or biomarkers and pathological conditions have been reported in the literature. However, there is a lack of clarity on the interaction between the coexistence of common skin microbes with skin physiology and subsequent development of clinical symptoms, and the role of biomarkers in mediating these changes before the development of skin disease. In this review, we aim to identify areas in which extensive research for the studied factors has already been conducted, and which research areas are under-represented. The SciFinder database was searched for articles containing key words including specific skin microbes, biomarkers, skin physiology and diseases from the beginning of the SciFinder data record to 26 April 2016, and we included an additional relevant recent publication from our group. Among the 8000 + articles selected, the frequency of keyword pairs between two roles [microscopic markers (microflora or biomarkers) and reactions (skin physiology or clinical symptoms, or skin disease)] was investigated. Associated research between the individual factors such as skin microflora or biomarkers (chosen based on our earlier publication) and specific biophysical parameters, symptoms or skin disease was identified. The present research heatmap emphasizes the significance of a structured review of research on concerned factor associations to identify early/subclinical clues that can be used to prevent progression to overt skin disease with the help of precise skin care or early intervention, as indicated by skin microflora, biomarkers and an interactive skin biophysics profile. The findings provide a novel approach to explore such associations and may guide future research directed towards predicting disease from early/subclinical symptoms.
Collapse
Affiliation(s)
- X Li
- Clinical Science APAC, Johnson & Johnson (China) Ltd, Shanghai Technology and Research Center, Shanghai, China
| | - L Xing
- Clinical Science APAC, Johnson & Johnson (China) Ltd, Shanghai Technology and Research Center, Shanghai, China
| | - R Lai
- External Innovation, Johnson & Johnson (China) Ltd, Minhang District, Shanghai, China
| | - C Yuan
- Skin and Cosmetic Research Department, Shanghai Skin Disease Hospital, Shanghai, China
| | - P Humbert
- Department of Dermatology, Research and Clinic Centre on the Tegument, Clinical Investigation Center, Besançon University Hospital, Besançon, France.,University of Franche-Comté, Inserm U1098, Besançon, France
| |
Collapse
|
13
|
Guadagno C, Millar D, Lai R, Mackay D, Pleban J, McClung C, Weinig C, Wang D, Ewers B. Use of transcriptomic data to inform biophysical models via Bayesian networks. Ecol Modell 2020. [DOI: 10.1016/j.ecolmodel.2020.109086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Zhang S, Wong K, Wang M, Teo K, Chuah S, Lai R, Lim S, Lee E, Hui J, Toh W. Optimising administration of MSC exosomes for cartilage repair in the clinic. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.03.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Oh DY, Hamilton E, Hanna D, Beeram M, Lee KW, Kang YK, Chaves J, Lee JY, Goodwin R, Vaklavas C, Rha SY, Elimova E, Mayordomo J, Ferrario C, Cobleigh M, Fortenberry A, Rowse G, Gray T, Lai R, Meric Bernstam F. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz420] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Meric-Bernstam F, Hanna D, Beeram M, Lee KW, Kang YK, Chaves J, Lee J, Goodwin R, Vaklavas C, Oh DY, Rha S, Elimova E, Mayordomo J, Ferrario C, Cobleigh M, Fortenberry A, Rowse G, Gray T, Lai R, Hamilton E. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
17
|
|
18
|
Ortiz L, Njah J, Marrocco A, Detweiler A, Milosevic J, Phinney D, Lai R, Choo A, Tan S, Lim S. Mesenchymal stem cells (hMSC) exosomes couple the RV/PA during Pulmonary fibrosis (PF). Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.03.580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Wheeler LA, Lai R, Woldemussie E. From the Lab to the Clinic: Activation of an Alpha-2 agonist Pathway is Neuroprotective in Models of Retinal and Optic Nerve Injury. Eur J Ophthalmol 2018; 9 Suppl 1:S17-21. [PMID: 10230601 DOI: 10.1177/112067219900901s09] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE The selective alpha-2 agonist brimonidine was used as a pharmacological probe to activate alpha 2 receptor-mediated neuroprotective signaling pathways and quantitate the enhancement of retinal ganglion cell survival and function in animals with ischemic retinal and optic nerve injury. METHODS Two animal models were used to achieve different methods of neuronal insult. The first model involved mechanical injury of the rat optic nerve after treatment with a single intraperitoneal (i.p.) dose of brimonidine or a control vehicle. The second model involving acute retinal ischemic/reperfusion injury was used in a variety of experiments in which rats were treated with either intraperitoneal brimonidine or single dose topical brimonidine at various strengths. In all cases retinal ischemia was induced and maintained followed by reperfusion. In some cases, TUNEL staining was performed on histologic sections of the retinas of rats that had been sacrificed after 24 hours. To examine the activation of neuronal survival pathways at the molecular level, rats were injected with i.p. brimonidine followed by the isolation of mRNAs from whole retinas 24 hours after ischemic injury. RESULTS Intraperitoneal brimonidine enhanced rat RGC survival and function in the partial crush injury model, and neuroprotection was dose-dependent. Topical application of brimonidine 1 hour before injury was effective in decreasing ischemic retinal injury. Ischemic retinas treated with brimonidine resulted with a large decrease in TUNEL staining. CONCLUSIONS Treatment with the alpha 2 adrenoreceptor agonist brimonidine was found to confer neuroprotection to retinal ganglion cells in two distinct models of neuronal injury resulting from acute retinal ischemia/reperfusion and calibrated optic nerve compression.
Collapse
Affiliation(s)
- L A Wheeler
- Department of Biological Sciences, Allergan Inc., Irvine, CA, USA
| | | | | |
Collapse
|
20
|
Toh W, Zhang S, Teo K, Chuah S, Lai R, Lim S. MSC exosomes alleviate pain and degeneration in A rat model of temporomandibular joint osteoarthritis. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Lai R, Lau YK. Superior Dislocation of the Patella Treated by Closed Reduction: A Rare Case Report and Review of the Literature. HONG KONG J EMERG ME 2017. [DOI: 10.1177/102490790701400406] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Superior dislocation of the patella is a rare condition. We report a 70-year-old gentleman with his patella lower pole osteophyte interlocked with the anterior femoral condyles after hyperextension. The patella was reduced successfully with proper reduction technique under sedation. The active range of movement ranged from full extension to 120-degree flexion a few minutes after reduction. He walked unaided afterwards. There was no knee problem in two years of follow-up. On reviewing the literature, only 20 cases were reported till year 2007 worldwide and 19 cases could be treated by closed reduction with or without sedation.
Collapse
|
22
|
Tu Q, Hao J, Zhou X, Yan L, Dai H, Sun B, Yang D, An S, Lv L, Jiao B, Chen C, Lai R, Shi P, Zhao X. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A. Oncogene 2017; 37:128-138. [PMID: 28892048 PMCID: PMC5759028 DOI: 10.1038/onc.2017.316] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 06/07/2017] [Accepted: 07/31/2017] [Indexed: 12/28/2022]
Abstract
Pancreatic cancer is among the deadliest malignancies; however, the genetic events that lead to pancreatic carcinogenesis in adults remain unclear. In vivo models in which these genetic alterations occur in adult animals may more accurately reflect the features of human cancer. In this study, we demonstrate that inactivation of Cdkn2b (p15ink4b) is necessary for induction of pancreatic cancer by oncogenic KRASG12D expression and inactivation of Tp53 and Cdkn2a in adult mouse pancreatic ductal cells (P60 or older). KRASG12D overexpression in these cells activated transforming growth factor-β signaling and expression of CDKN2B, which, along with CDKN2A, led to cellular senescence and protected cells from KRAS-mediated transformation via inhibition of retinoblastoma phosphorylation. These results show a critical role of CDKN2B inactivation in pancreatic carcinogenesis, and provide a useful adult animal model by genetic engineering via lentiviral delivery.
Collapse
Affiliation(s)
- Q Tu
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China
| | - J Hao
- State Key Laboratory of Genetic Resources and Evolution, Laboratory of Evolutionary and Functional Genomics, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China
| | - X Zhou
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China
| | - L Yan
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming Primate Research Center, Chinese Academy of Sciences, Kunming, China
| | - H Dai
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China
| | - B Sun
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China
| | - D Yang
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China
| | - S An
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China
| | - L Lv
- Kunming Primate Research Center, Chinese Academy of Sciences, Kunming, China
| | - B Jiao
- State Key Laboratory of Genetic Resources and Evolution, Laboratory of Evolutionary and Functional Genomics, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China
| | - C Chen
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China
| | - R Lai
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China
| | - P Shi
- State Key Laboratory of Genetic Resources and Evolution, Laboratory of Evolutionary and Functional Genomics, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China
| | - X Zhao
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming, China.,Kunming Primate Research Center, Chinese Academy of Sciences, Kunming, China.,KIZ-SU Joint Laboratory of Animal Model and Drug Development, College of Pharmaceutical Sciences, Soochow University, Suzhou, China
| |
Collapse
|
23
|
Scott D, Pitcher B, Liu Y, Boyle M, Mottok A, Said J, Chadburn A, Lai R, Jung S, Bartlett N, Leonard J, Kaplan L, Hsi E. HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS-A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- D.W. Scott
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - B. Pitcher
- Alliance Statistics and Data Center; Duke University; Durham NC USA
| | - Y. Liu
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - M. Boyle
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - A. Mottok
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - J. Said
- Pathology and Laboratory Medicine; UCLA School of Medicine; Los Angeles CA USA
| | - A. Chadburn
- Pathology and Cell Biology; Weill Cornell Medical College; New York NY USA
| | - R. Lai
- Laboratory Medicine and Pathology; University Alberta; Edmonton AB Canada
| | - S. Jung
- Alliance Statistics and Data Center; Duke University; Durham NC USA
| | - N.L. Bartlett
- Department of Medicine; Washington University School of Medicine; St. Louis MO USA
| | - J.P. Leonard
- Department of Medicine; Weill Cornell Medical College; New York NY USA
| | - L.D. Kaplan
- Adult Lymphoma Program; UCSF; San Francisco CA USA
| | - E.D. Hsi
- Department of Laboratory Medicine; Cleveland Clinic; Cleveland OH USA
| |
Collapse
|
24
|
Shang X, Song X, Faller C, Lai R, Li H, Cerny R, Niu W, Guo J. Fluorogenic protein labeling using a genetically encoded unstrained alkene. Chem Sci 2016; 8:1141-1145. [PMID: 28451254 PMCID: PMC5369545 DOI: 10.1039/c6sc03635j] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Accepted: 09/23/2016] [Indexed: 12/26/2022] Open
Abstract
A new fluorogenic bioorthogonal reaction between styrene (an unstrained alkene) and a tetrazine was developed.
We developed a new fluorogenic bioorthogonal reaction that is based on the inverse electron-demand Diels–Alder reaction between styrene (an unstrained alkene) and a simple tetrazine. The reaction forms a new fluorophore with no literature precedent. We have identified an aminoacyl-tRNA synthetase/tRNA pair for the efficient and site-specific incorporation of a styrene-containing amino acid into proteins in response to amber nonsense codon. Fluorogenic labeling of purified proteins and intact proteins in live cells were demonstrated. The fluorogenicity of the styrene–tetrazine reaction can be potentially applied to the study of protein folding and function under physiological conditions with low background fluorescence interference.
Collapse
Affiliation(s)
- X Shang
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - X Song
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - C Faller
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - R Lai
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - H Li
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - R Cerny
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - W Niu
- Department of Chemical & Biomolecular Engineering , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| | - J Guo
- Department of Chemistry , University of Nebraska-Lincoln , Lincoln , NE 68588 , USA .
| |
Collapse
|
25
|
Loo CK, Gálvez V, O'Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, Harper S, Somogyi AA, Lai R, Weickert CS, Glue P. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 2016; 134:48-56. [PMID: 27028832 DOI: 10.1111/acps.12572] [Citation(s) in RCA: 141] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/22/2016] [Indexed: 01/17/2023]
Abstract
OBJECTIVE This pilot study assessed the feasibility, efficacy and safety of an individual dose-titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) routes for treating depression with ketamine. METHOD Fifteen treatment-refractory depressed participants received ketamine or midazolam (control treatment) in a multiple crossover, double-blind study. Ketamine was administered by IV (n = 4), IM (n = 5) or SC (n = 6) injection. Dose titration commenced at 0.1 mg/kg, increasing by 0.1 mg/kg up to 0.5 mg/kg, given in separate treatment sessions separated by ≥1 week, with one placebo control treatment randomly inserted. Mood, psychotomimetic and hemodynamic effects were assessed and plasma ketamine concentrations assayed. RESULTS Twelve participants achieved response and remission criteria, achieved at doses as low as 0.1 mg/kg. All three routes of administration resulted in comparable antidepressant effects. Fewest adverse effects were noted with the SC route. Antidepressant response, adverse effects and ketamine concentrations were dose-related. CONCLUSION Antidepressant response occurred at a range of doses and at <0.5 mg/kg. The dose-titration approach is a practical method for optimizing the efficacy - side-effects trade-off on an individual patient basis. This pilot study provides preliminary evidence for SC injection as a practical, feasible and efficacious treatment approach.
Collapse
Affiliation(s)
- C K Loo
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.,Black Dog Institute, Randwick, NSW, Australia.,Wesley Hospital, Kogarah, NSW, Australia.,St George Hospital, Kogarah, NSW, Australia
| | - V Gálvez
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.,Black Dog Institute, Randwick, NSW, Australia
| | - E O'Keefe
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
| | - P B Mitchell
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.,Black Dog Institute, Randwick, NSW, Australia
| | - D Hadzi-Pavlovic
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.,Black Dog Institute, Randwick, NSW, Australia
| | - J Leyden
- Wesley Hospital, Kogarah, NSW, Australia.,Royal North Shore Hospital, St Leonards, NSW, Australia
| | - S Harper
- Wesley Hospital, Kogarah, NSW, Australia.,University of New South Wales, Randwick, NSW, Australia
| | - A A Somogyi
- University of Adelaide, Adelaide, SA, Australia.,Royal Adelaide Hospital, Adelaide, SA, Australia
| | - R Lai
- Macquarie Hospital, Sydney, NSW, Australia
| | - C S Weickert
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.,Schizophrenia Research Institute, Randwick, NSW, Australia.,Neuroscience Research Australia, Randwick, NSW, Australia
| | - P Glue
- Psychological Medicine, University of Otago, Dunedin, New Zealand
| |
Collapse
|
26
|
Zhang S, Chu W, Lai R, Hui J, Lee E, Lim S, Toh W. Human Mesenchymal Stem Cell-Derived Exosomes Promote Orderly Cartilage Regeneration in an Immunocompetent Rat Osteochondral Defect Model. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.035] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
Fang Y, Long C, Bai X, Liu W, Rong M, Lai R, An S. Two new types of allergens from the cockroach, Periplaneta americana. Allergy 2015; 70:1674-8. [PMID: 26361742 DOI: 10.1111/all.12766] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/08/2015] [Indexed: 01/04/2023]
Abstract
Periplaneta americana cockroach is an important source of inhalant indoor allergen resource, and there are more than twenty IgE-binding components identified in P. americana, but only nine allergens were characterized. Our knowledge about cockroach allergens remains poor. In this work, two novel allergen proteins Per a 11 (alpha-amylase) and Per a 12 (chitinase) with molecular weight around 55 and 45 kDa, respectively, were purified and characterized from the midgut of cockroaches. Their primary sequences were determined by Edman degradation, mass spectrometry, and cDNA cloning. Sera from 39 and 30 of 47 (83.0% and 63.8%) patients reacted to Per a 11 and Per a 12 on immunoblots, respectively. The allergenicity of Per a 11 and Per a 12 was further confirmed by competitive ELISA, basophil activation test (BAT), and skin prick test (SPT). They appear to be of importance for the allergic reactions induced by cockroach and have a potential for component-based diagnosis of allergy.
Collapse
Affiliation(s)
- Y. Fang
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
| | - C. Long
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
| | - X. Bai
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
| | - W. Liu
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
| | - M. Rong
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
| | - R. Lai
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
- Life Sciences College of Nanjing Agricultural University; Nanjing Jiangsu China
- Joint Laboratory of Natural peptide; Chinese Academy of Sciences; University of Science and Technology of China and Kunming Institute of Zoology; Yunnan China
| | - S. An
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province; Kunming Institute of Zoology; Kunming Yunnan China
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Yunnan China
| |
Collapse
|
28
|
Roberts-Rapp L, Ansell P, Kular R, Song M, Sokolova I, Gan H, Papadopoulos K, Lassman A, Merrell R, Kumthekar P, Scott A, Gomez E, Fischer J, Bhathena A, Holen K, Lai R, Reardon D, van den Bent M. 28PD Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv518.03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Lai R, Woolley DJ, Lawes GS. The effect of inter-fruit competition, type of fruiting lateral and time of anthesis on the fruit growth of kiwifruit(Actinidia deliciosa). ACTA ACUST UNITED AC 2015. [DOI: 10.1080/00221589.1990.11516034] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
Lai R, Woolley DJ, Lawes GS. Patterns of assimilate transport from leaves to fruit within a kiwifruit (Actinidia deliciosa) lateral. ACTA ACUST UNITED AC 2015. [DOI: 10.1080/14620316.1988.11515917] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Alqahtani H, Gopal K, Gupta N, Jung K, Alshareef A, Ye X, Wu F, Li L, Lai R. DDX17 (P72), a Sox2 binding partner, promotes stem-like features conferred by Sox2 in a small cell population in estrogen receptor-positive breast cancer. Cell Signal 2015; 28:42-50. [PMID: 26569340 DOI: 10.1016/j.cellsig.2015.11.004] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 11/09/2015] [Indexed: 12/20/2022]
Abstract
We have previously demonstrated the existence of two phenotypically distinct cell subsets in estrogen receptor (ER)-positive breast cancer (BC) based on their differential response to a Sox2 reporter (SRR2), with reporter responsive (RR) cells being more tumorigenic and stem-like than reporter unresponsive (RU) cells. To delineate the molecular mechanisms underlying this phenotypic dichotomy, we tested our hypothesis that Sox2, which is a key regulator of the RR phenotype, is under the control of its binding partners. In this study, we focused on DDX17, known to be a transcription co-activator and found to be a Sox2 binding partner by liquid chromatography-mass spectrometry. Using immunoprecipitation, we confirmed the binding between DDX17 and Sox2, although this interaction was largely restricted to RR cells. While DDX17 was found in both the cytoplasm and nuclei in RU cells, it is confined to the nuclei in RR cells. siRNA knockdown of DDX17 in RR cells substantially decreased the Sox2-SRR2 binding and significantly decreased the SRR2 reporter activity without affecting the protein level of Sox2. Using ChIP-PCR, DDX17 knockdown also significantly decreased the binding of Sox2 to genomic SRR2, as well as 3 of its specific gene targets including MUC15, CCND1 and CD133. Correlating with these findings, siRNA knockdown of DDX17 significantly reduced soft agar colony formation and mammosphere formation in RR cells but not RU cells. To conclude, DDX17 is a Sox2-binding protein in ER-positive BC. In RR but not RU cells, DDX17 enhances the tumorigenic and stem-like features of Sox2 by promoting its binding to its target genes.
Collapse
Affiliation(s)
- H Alqahtani
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - K Gopal
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - N Gupta
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - K Jung
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - A Alshareef
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - X Ye
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - F Wu
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - L Li
- Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada
| | - R Lai
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
| |
Collapse
|
32
|
Jeyanathan M, Thanthrige-Don N, Afkhami S, Lai R, Damjanovic D, Zganiacz A, Feng X, Yao XD, Rosenthal KL, Medina MF, Gauldie J, Ertl HC, Xing Z. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Mucosal Immunol 2015; 8:1373-87. [PMID: 25872483 DOI: 10.1038/mi.2015.29] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 03/20/2015] [Indexed: 02/07/2023]
Abstract
Pulmonary tuberculosis (TB) remains to be a major global health problem despite many decades of parenteral use of Bacillus Calmette-Guérin (BCG) vaccine. Developing safe and effective respiratory mucosal TB vaccines represents a unique challenge. Over the past decade or so, the human serotype 5 adenovirus (AdHu5)-based TB vaccine has emerged as one of the most promising candidates based on a plethora of preclinical and early clinical studies. However, anti-AdHu5 immunity widely present in the lung of humans poses a serious gap and limitation to its real-world applications. In this study we have developed a novel chimpanzee adenovirus 68 (AdCh68)-vectored TB vaccine amenable to the respiratory route of vaccination. We have evaluated AdCh68-based TB vaccine for its safety, T-cell immunogenicity, and protective efficacy in relevant animal models of human pulmonary TB with or without parenteral BCG priming. We have also compared AdCh68-based TB vaccine with its AdHu5 counterpart in both naive animals and those with preexisting anti-AdHu5 immunity in the lung. We provide compelling evidence that AdCh68-based TB vaccine is not only safe when delivered to the respiratory tract but, importantly, is also superior to its AdHu5 counterpart in induction of T-cell responses and immune protection, and limiting lung immunopathology in the presence of preexisting anti-AdHu5 immunity in the lung. Our findings thus suggest AdCh68-based TB vaccine to be an ideal candidate for respiratory mucosal immunization, endorsing its further clinical development in humans.
Collapse
Affiliation(s)
- M Jeyanathan
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - N Thanthrige-Don
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - S Afkhami
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - R Lai
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - D Damjanovic
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - A Zganiacz
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - X Feng
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - X-D Yao
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - K L Rosenthal
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - M Fe Medina
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - J Gauldie
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| | - H C Ertl
- Department of Immunology, The Wistar Institute, Philadelphia, Pennsylvania, USA
| | - Z Xing
- McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine and Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
33
|
Van den Bent M, Roberts-Rapp L, Ansell P, Kular R, Song M, Sokolova I, Gan H, Papadopoulos K, Lassman A, Merrell R, Kumthekar P, Scott A, Gomez E, Fischer J, Bhathena A, Holen K, Lai R, Reardon D. 2903 Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31620-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Chiu C, Yang C, Shih J, Huang M, Su W, Lai R, Wang C, Hsiao S, Lin Y, Ho C, Wu M, Hsia T, Lai C, Lee K, Lin C, Chang F, Chuang C, Yeh D, Perng R. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Non-Small Cell Lung Cancer with G719X/L861Q/S768I Mutations. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Crespo Alonso M, Arca M, Isaia F, Lai R, Lippolis V, Callear SK, Caricato M, Pasini D, Coles SJ, Aragoni MC. Stereospecific generation of homochiral helices in coordination polymers built from enantiopure binaphthyl-based ligands. CrystEngComm 2014. [DOI: 10.1039/c4ce01101e] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The novel enantiopure spacer 2,2′-dimethoxy-1,1′-binaphthyl-3,3′-bis(4-pyridyl-amido) has been designed to prepare helical coordination polymers here investigated by means of experimental and theoretical data.
Collapse
Affiliation(s)
- M. Crespo Alonso
- Dipartimento di Scienze Chimiche e Geologiche
- Università degli Studi di Cagliari
- Cittadella Universitaria
- 09042 Monserrato Cagliari, Italy
| | - M. Arca
- Dipartimento di Scienze Chimiche e Geologiche
- Università degli Studi di Cagliari
- Cittadella Universitaria
- 09042 Monserrato Cagliari, Italy
| | - F. Isaia
- Dipartimento di Scienze Chimiche e Geologiche
- Università degli Studi di Cagliari
- Cittadella Universitaria
- 09042 Monserrato Cagliari, Italy
| | - R. Lai
- Dipartimento di Scienze Chimiche e Geologiche
- Università degli Studi di Cagliari
- Cittadella Universitaria
- 09042 Monserrato Cagliari, Italy
| | - V. Lippolis
- Dipartimento di Scienze Chimiche e Geologiche
- Università degli Studi di Cagliari
- Cittadella Universitaria
- 09042 Monserrato Cagliari, Italy
| | - S. K. Callear
- ISIS Facility
- Rutherford Appleton Laboratory
- Didcot, UK
| | - M. Caricato
- Department of Chemistry and INSTM Research Unit
- University of Pavia
- 27100 Pavia, Italy
| | - D. Pasini
- Department of Chemistry and INSTM Research Unit
- University of Pavia
- 27100 Pavia, Italy
| | - S. J. Coles
- UK National Crystallography Service
- Chemistry
- Faculty of Natural and Environmental Sciences
- University of Southampton
- Southampton, UK
| | - M. C. Aragoni
- Dipartimento di Scienze Chimiche e Geologiche
- Università degli Studi di Cagliari
- Cittadella Universitaria
- 09042 Monserrato Cagliari, Italy
| |
Collapse
|
36
|
Tse R, Lai R, Cala A. Increasing blood alcohol detection and blood alcohol levels in suicidal hanging from 2007 to 2011. Pathology 2014. [DOI: 10.1097/01.pat.0000443652.31592.ea] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Bie L, Li Y, Yuan H, Bondy M, Bainbridge M, Jhangiani S, Jalali A, Plon SE, Armstrong G, Bernstein J, Claus E, Davis F, Houlston R, Il'yasova D, Jenkins R, Johansen C, Lachance D, Lai R, Lau C, Merrell R, Olson S, Sadetzki S, Schildkraut J, Shete S, Barnholtz-Sloan J, Wrensch M, Consortium TG, Melin B, Gibbs RA, Haberler C, Czech T, Chocholous M, Dorfer C, Slavc I, Hayashi S, Sasaki H, Kimura T, Nakamura T, Miwa T, Hirose Y, Yoshida K, Jalali A, Bainbridge M, Jhangiani S, Plon SE, Armstrong G, Bernstein J, Claus E, Davis F, Houlston R, Il'yasova D, Jenkins R, Johansen C, Lachance D, Lai R, Lau C, Merrell R, Olson SH, Sadetzki S, Schildkraut J, Shete S, Barnholtz-Sloan J, Wrensch M, Melin B, Gibbs RA, Bondy M, Jenkins R, Wrensch M, Kollmeyer T, Armstrong G, Olson S, Lai R, Lachance D, Lau C, Claus E, Barnholtz-Sloan J, Il'yasova D, Schildkraut J, Houlston R, Shete S, Bernstein J, Davis F, Merrell R, Johansen C, Sadetzki S, Consortium TG, Melin B, Bondy M, Palmer J, Li J, Kenyon L, Andrews D, Kim L, Glass J, Werner-Wasik M, Shi W, Takayanagi S, Mukasa A, Aihara K, Saito K, Otani R, Tanaka S, Nakatomi H, Aburatani H, Ichimura K, Ueki K, Saito N, Walsh KM, Decker PA, Eckel-Passow JE, Molinaro AM, Hansen HM, Rice T, Zheng S, Kollmeyer T, Berger MS, Chang SM, Prados MD, Rynearson A, Caron A, Kosel ML, Lachance DH, O'Neill BP, Giannini C, Wiencke JK, Jenkins RB, Wrensch MR, Wang Z, Bao Z, Jiang T, Wang Z, Bao Z, Jiang T. MOLECULAR EPIDEMIOLGOY. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Amirian ES, Scheurer ME, Wrensch M, Olson SH, Lai R, Lachance D, Armstrong G, Zhou R, Wiemels J, Lau C, Claus E, Barnholtz-Sloan J, Il'yasova D, Schildkraut J, Houlston R, Shete S, Bernstein J, Jenkins R, Davis F, Merrell R, Johansen C, Sadetzki S, Melin B, Bondy M, Dardis C, Dembowska-Baginska B, Swieszkowska E, Drogosiewicz M, Polnik MP, Filipek I, Grudzinska M, Grajkowska W, Perek D, Flores K, Crawford J, Piccioni D, Lemus H, Lindsay S, Kesari S, Bricker P, Fonkem E, Ebue E, Song J, Harris F, Thawani N, DiPatre PL, Newell-Rogers MK, Fonkem E, Gittleman H, Kruchko C, Ostrom Q, Chen Y, Farah P, Ondracek A, Wolinsky Y, Barnholtz-Sloan J, Griffin J, Tobin R, Newell-Rogers MK, Ebwe E, Fonkem E, Johnson D, Leeper H, Uhm J, Lee A, Back M, Gzell C, Kastelan M, Wheeler H, Ostrom Q, Kruchko C, Gittleman H, Chen Y, Ondracek A, Farah P, Wolinsky Y, Barnholtz-Sloan J, Lopez E, Sepulveda C, Diego-Perez J, Betanzos Y, de Leon AP, Prabhu V, Perry E, Melian E, Barton K, Lee J, Anderson D, Urgoiti GR, Singh A, Tsang RY, Nordal R, Lim G, Chan J, Starreveld Y, de Robles P, Biagioni B, Hamilton M, Easaw J, Senerchia A, Eleuterio S, Souza E, Cappellano A, Seixas T, Cavalheiro S, Saba N, Torres-Carranza A, Canales-Martinez LC, Perez-Cardenas S, Miranda-Maldonado I, Barbosa-Quintana O, de Leon AMP, Umemura Y, Ronan L, van Zanten SV, Jansen M, van Vuurden D, Vandertop P, Kaspers GJ, Wallach J, LaSala P, Kalnicki S, Garg M, Wong TT, Ho DM, Chang KP, Yen SH, Guo WY, Chang FC, Liang ML, Chen HHS, Chen YW, Pan DHC, Chung WY, Yoo H, Jung KW, Lee SH, Shin SH, Ha J, Won YJ, Yoon H, Offor O, Helenowski I, Bhandari R, Raparia K, Marymont M, DeCamp M, de Hoyos A, Chandler J, Bendok B, Chmura S, Mehta M. EPIDEMIOLOLGY. Neuro Oncol 2013; 15:iii32-iii36. [PMCID: PMC3823890 DOI: 10.1093/neuonc/not175] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2023] Open
|
39
|
Beckles Z, Glover S, Ashe J, Stockton S, Boynton J, Lai R, Alderson P. Searching CINAHL did not add value to clinical questions posed in NICE guidelines. J Clin Epidemiol 2013; 66:1051-7. [PMID: 23835312 DOI: 10.1016/j.jclinepi.2013.04.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Revised: 04/03/2013] [Accepted: 04/16/2013] [Indexed: 11/29/2022]
Abstract
OBJECTIVES This study aims to quantify the unique useful yield from the Cumulative Index to Nursing and Allied Health Literature (CINAHL) database to National Institute for Health and Clinical Excellence (NICE) clinical guidelines. A secondary objective is to investigate the relationship between this yield and different clinical question types. It is hypothesized that the unique useful yield from CINAHL is low, and this database can therefore be relegated to selective rather than routine searching. STUDY DESIGN AND SETTING A retrospective sample of 15 NICE guidelines published between 2005 and 2009 was taken. Information on clinical review question type, number of references, and reference source was extracted. RESULTS Only 0.33% (95% confidence interval: 0.01-0.64%) of references per guideline were unique to CINAHL. Nursing- or allied health (AH)-related questions were nearly three times as likely to have references unique to CINAHL as non-nursing- or AH-related questions (14.89% vs. 5.11%), and this relationship was found to be significant (P<0.05). No significant relationship was found between question type and unique CINAHL yield for drug-related questions. CONCLUSIONS The very low proportion of references unique to CINAHL strongly suggests that this database can be safely relegated to selective rather than routine searching. Nursing- and AH-related questions would benefit from selective searching of CINAHL.
Collapse
Affiliation(s)
- Zosia Beckles
- National Collaborating Centre for Women's and Children's Health, King's Court, 4th floor, 2-16 Goodge Street, London W1T 2QA, UK.
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
BACKGROUND There are many pathological conditions leading to an elevated unconjugated bilirubin level (hyperbilirubinaemia) in neonates. Currently the standard therapies for unconjugated hyperbilirubinaemia include phototherapy and exchange transfusion. In addition to phototherapy, clofibrate has been studied as a treatment for hyperbilirubinaemia in several countries. OBJECTIVES To determine the efficacy and safety of clofibrate in combination with phototherapy versus phototherapy alone in unconjugated neonatal hyperbilirubinaemia. SEARCH METHODS Randomised controlled trials were identified by searching MEDLINE (1950 to April 2012) before being translated for use in The Cochrane Library, EMBASE 1980 to April 2012 and CINAHL databases. All searches were re-run on 2 April 2012. SELECTION CRITERIA We included trials where neonates with hyperbilirubinaemia received either clofibrate in combination with phototherapy or phototherapy alone or placebo in combination with phototherapy. DATA COLLECTION AND ANALYSIS Data were extracted and analysed independently by two review authors (MG and HM). Treatment effects on the following outcomes were determined: mean change in bilirubin levels, mean duration of treatment with phototherapy, number of exchange transfusions needed, adverse effects of clofibrate, bilirubin encephalopathy and neonatal mortality. Study authors were contacted for additional information. Studies were analysed for methodological quality in a 'Risk of bias' table. MAIN RESULTS Fifteen studies (two including preterm neonates and 13 including term neonates) were included in this review. All but one of the included studies were conducted in Iran. For preterm neonates, there was a significantly lower bilirubin level in the 100 mg/kg clofibrate group compared to the control group with a mean difference of -1.37 mg/dL (95% CI -2.19 mg/dL to -0.55 mg/dL) (-23 µmol/L; 95% CI -36 µmol/L to -9 µmol/L) after 48 hours. For the term neonates, there were significantly lower bilirubin levels in the clofibrate group compared to the control group after both 24 and 48 hours of treatment with a weighted mean difference of -2.14 mg/dL (95% CI -2.53 mg/dL to -1.75 mg/dL) (-37 µmol/L; 95% CI -43 µmol/L to -30 µmol/L] and -1.82 mg/dL (95% CI -2.25 mg/dL to -1.38 mg/dL) (-31 µmol/L; 95% CI -38 µmol/L to -24 µmol/L), respectively.There was a significantly lower duration of phototherapy in the clofibrate group compared to the control group for both preterm and term neonates with a weighted mean difference of -23.82 hours (95% CI -30.46 hours to -17.18 hours) and -25.40 hours (95% CI -28.94 hours to -21.86 hours), respectively.None of the studies reported on bilirubin encephalopathy rates, neonatal mortality rates, or the levels of parental or staff satisfactions with the interventions. AUTHORS' CONCLUSIONS There are insufficient data from different countries on the use of clofibrate in combination with phototherapy for hyperbilirubinaemia to make recommendations for practice. There is a need for larger trials to determine how effective clofibrate is in reducing the need for, and duration of, phototherapy in term and preterm infants with hyperbilirubinaemia.
Collapse
Affiliation(s)
- Maryam Gholitabar
- National Collaborating Centre for Women’s and Children’s Health, London, UK
| | | | | | | | | |
Collapse
|
41
|
Xu P, Shi M, Lai R, Chen XX. Differences in numbers of termicins expressed in two termite species affected by fungal contamination of their environments. Genet Mol Res 2012; 11:2247-57. [PMID: 22614454 DOI: 10.4238/2012.may.10.2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Termicin is a defensin-like antimicrobial peptide of termites that has strong antifungal activity. Fifty-six different termicin mRNAs encoding 46 different peptides were amplified and identified from Odontotermes formosanus (Termitidae), a species that inhabits environments with a large variety of microbial fauna. In contrast, only 38 different termicin mRNAs encoding 21 different peptides were amplified and identified from Reticulitermes chinensis (Rhinotermitidae). All mRNAs were amplified by reverse transcript PCR, with primers designed from reported termicin mRNA sequences. All of these genes showed high intraspecific sequence identity and were found to be highly homologous with other reported termicin genes. These two termite species live in different environments; the latter encounters relatively fewer pathogens in its habitat. We conclude that differences in microenvironmental pressure can affect the number of termicin genes expressed in termite species.
Collapse
Affiliation(s)
- P Xu
- Ministry of Agriculture, Key Laboratory of Agricultural Entomology, Institute of Insect Sciences, Zhejiang University, Hangzhou, China
| | | | | | | |
Collapse
|
42
|
Borbath I, Verbrugghe L, Lai R, Gigot J, Humblet Y, Piessevaux H, Sempoux C. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer 2012; 48:990-6. [DOI: 10.1016/j.ejca.2011.11.006] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Revised: 10/26/2011] [Accepted: 11/05/2011] [Indexed: 01/07/2023]
|
43
|
Chong C, Fong L, Lai R, Lau WKO, Hartmann M, Chia SE. Erratum: The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study. Prostate Cancer Prostatic Dis 2012. [DOI: 10.1038/pcan.2012.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2012; 23:86-93. [PMID: 21471564 PMCID: PMC3276322 DOI: 10.1093/annonc/mdr033] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2010] [Revised: 01/19/2011] [Accepted: 01/20/2011] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND The IALT, JBR.10, ANITA and Cancer and Leukemia Group B 9633 trials compared adjuvant chemotherapy with observation for patients with resected non-small-cell lung cancer (R-NSCLC). Data from the metastatic setting suggest high tumor class III beta-tubulin (TUBB3) expression is a determinant of insensitivity to tubulin-targeting agents (e.g. vinorelbine, paclitaxel). In 265 patients from JBR.10 (vinorelbine-cisplatin versus observation), high TUBB3 was an adverse prognostic factor and was associated (nonsignificantly) with 'greater' survival benefit from chemotherapy. We explored this further in additional patients from JBR.10 and the other three trials. PATIENTS AND METHODS TUBB3 immunohistochemical staining was scored for 1149 patients on the four trials. The original JBR.10 cut-off scores were used to classify tumors as TUBB3 high or low. The prognostic and predictive value of TUBB3 on disease-free survival (DFS) and overall survival (OS) was assessed by Cox models stratified by trial and adjusted for clinical factors. RESULTS High TUBB3 expression was prognostic for OS [hazard ratio (HR)=1.27 (1.07-1.51), P=0.008) and DFS [HR=1.30 (1.11-1.53), P=0.001). TUBB3 was not predictive of a differential treatment effect [interaction P=0.20 (OS), P=0.23 (DFS)]. Subset analysis (n=420) on vinorelbine-cisplatin gave similar results. CONCLUSIONS The prognostic effect of high TUBB3 expression in patients with R-NSCLC has been validated. We were unable to confirm a predictive effect for TUBB3.
Collapse
Affiliation(s)
- T Reiman
- Department of Medicine, Dalhousie University and Department of Oncology, Saint John Regional Hospital, Saint John.
| | - R Lai
- Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, Canada; Departments of
| | | | - E Paris
- Biostatistics and Epidemiology
| | - J C Soria
- Medicine, Institut Gustave-Roussy, Paris, France
| | - R Rosell
- Department of Medicine, Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - M Taron
- Department of Medicine, Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - S Graziano
- Department of Medicine, State University of New York, Upstate Medical University, Syracuse
| | - R Kratzke
- Department of Medicine, University of Minnesota, Minneapolis, USA
| | - L Seymour
- NCIC Clinical Trials Group, Kingston
| | - F A Shepherd
- Department of Medicine, Princess Margaret Hospital, University Health Network, Toronto, Canada
| | | | - P Sève
- Department of Internal Medicine, Hopital de la Croix Rousse
| |
Collapse
|
45
|
Hu P, Lai R, Xie D. Gentamicin affects connexin 26 expression in the cochlear lateral wall. B-ENT 2012; 8:77-84. [PMID: 22896926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Abstract
OBJECTIVES/HYPOTHESIS Aminoglycosides may decrease the expression of some proteins participating in ion-exchange in the cochlear lateral wall. Connexin 26 expression in the lateral wall may play a role in acquired hearing loss by maintaining the endocochlear potential and potassium concentration in the endolymph. We examined the effects of gentamicin on the expression of connexin 26 to obtain a better understanding of aminoglycoside ototoxicity. METHODS We detected changes in connexin 26 protein and mRNA expression in the cochlear lateral wall using immunohistochemistry staining, western blotting, and real-time PCR in rats after administration of a single dose of gentamicin. RESULTS The expression of connexin 26 increased over time in type III fibrocytes after gentamicin administration. Elevated protein levels were detected 3 h after the single injection of gentamicin; while, mRNA levels increased after 24 h. CONCLUSION Connexin 26 plays an important role in the acute effects of high-dose gentamicin and is probably involved in the pathogenesis of ototoxic deafness.
Collapse
Affiliation(s)
- P Hu
- Institute of Otology, Department of Otolaryngology and Head and Neck surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China
| | | | | |
Collapse
|
46
|
An S, Ma D, Wei JF, Yang X, Yang HW, Yang H, Xu X, He S, Lai R. A novel allergen Tab y 1 with inhibitory activity of platelet aggregation from salivary glands of horseflies. Allergy 2011; 66:1420-7. [PMID: 21848516 DOI: 10.1111/j.1398-9995.2011.02683.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Horsefly sting causes allergic reactions in human body. However, our knowledge on horsefly allergens remains poor. OBJECTIVES To identify the novel horsefly allergens and characterize their properties. METHODS A native allergen protein Tab y 1 (apyrase) was purified from the salivary glands of the horsefly Tabanus yao Macquart by gel filtration and ion exchange chromatography. Its sequence was determined by Edman degradation and cDNA cloning. Its allergenicity was assessed by immunoblotting for specific IgE, basophil activation test, skin prick test (SPT), and competitive enzyme-linked immunosorbent assay (ELISA). RESULTS Tab y 1 showed a single diffusion band of 70 kDa on SDS-PAGE. Seventy percent (7/10) of patients with horsefly allergy tested positive to Tab y 1 in SPT; sera from 81% (30/37) of patients reacted to Tab y 1 on western blots. Purified Tab y 1 reduced approximately 42% sera IgE reactivity to horsefly salivary gland extract on a competitive ELISA. Tab y 1 upregulated the expression of CD63 and CCR3 on passively sensitized basophils by up to approximately 4.9-fold. Tab y 1 also showed enzymatic activity to hydrolyze ATP and ADP, and potent antiplatelet aggregation and antithrombotic activities. CONCLUSION The current work identified a novel major allergen of horsefly, Tab y 1, with antiplatelet aggregation and antithrombotic activities, which implicates Tab y 1 in helping horseflies suck host blood, meanwhile causing allergy in their human hosts.
Collapse
Affiliation(s)
- S An
- Biotoxin Units of Key Laboratory of Animal Models and Human Disease Mechanisms, Kunming Institute of Zoology, Chinese Academy of Sciences, China
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Wong B, Lai R, Chan P, Lee N. A hospital outbreak of seasonal influenza involving three health care workers – implications on the optimal choice of respiratory protection. BMC Proc 2011. [PMCID: PMC3239512 DOI: 10.1186/1753-6561-5-s6-p100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023] Open
|
48
|
Lai R, Xie L, Wu X, Zhang S, Du Y, Zhao S, Zheng Y, Sun Y, LI H, Chen J, LI Z, Liu L, Tang X, Wang L, Wang Y, Han M, Liu C, Wang J, Li H, Liu S. Gene expression signature comparison for solid tumor chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Ma D, Xu X, An S, Liu H, Yang X, Andersen JF, Wang Y, Tokumasu F, Ribeiro JMC, Francischetti IMB, Lai R. A novel family of RGD-containing disintegrins (Tablysin-15) from the salivary gland of the horsefly Tabanus yao targets αIIbβ3 or αVβ3 and inhibits platelet aggregation and angiogenesis. Thromb Haemost 2011; 105:1032-45. [PMID: 21475772 DOI: 10.1160/th11-01-0029] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Accepted: 02/08/2011] [Indexed: 11/05/2022]
Abstract
A novel family of RGD-containing molecules (Tablysin-15) has been molecularly characterised from the salivary gland of the haematophagous horsefly Tabanus yao. Tablysin-15 does not share primary sequence homology to any disintegrin discovered so far, and displays an RGD motif in the N-terminus of the molecule. It is also distinct from disintegrins from Viperidae since its mature form is not released from a metalloproteinase precursor. Tablysin-15 exhibits high affinity binding for platelet αIIbβ3 and endothelial cell αVβ3 integrins, but not for α5β1 or α2β1. Accordingly, it blocks endothelial cell adhesion to vitronectin (IC50 ~1 nM) and marginally to fibronectin (IC50 ~1 μM), but not to collagen. It also inhibits fibroblast growth factor (FGF)-induced endothelial cell proliferation, and attenuates tube formation in vitro. In platelets, Tablysin-15 inhibits aggregation induced by collagen, ADP and convulxin, and prevents static platelet adhesion to immobilised fibrinogen. In addition, solid-phase assays and flow cytometry demonstrates that αIIbβ3 binds to Tablysin-15. Moreover, immobilised Tablysin-15 supports platelet adhesion by a mechanism which was blocked by anti-integrin αIIbβ3 monoclonal antibody (e.g. abciximab) or by EDTA. Furthermore, Tablysin-15 dose-dependently attenuates thrombus formation to collagen under flow. Consistent with these findings, Tablysin-15 displays antithrombotic properties in vivo suggesting that it is a useful tool to block αIIbβ3, or as a prototype to develop antithrombotics. The RGD motif in the unique sequence of Tablysin-15 represents a novel template for studying the structure-function relationship of the disintegrin family of inhibitors.
Collapse
Affiliation(s)
- D Ma
- Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, Yunnan, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Onetti Muda A. Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. Eur J Histochem 2011; 54:e38. [PMID: 20839414 PMCID: PMC3167316 DOI: 10.4081/ejh.2010.e38] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer. Aim of the present study is to evaluate the variations of hENT1 expression in ampullary carcinomas and to correlate such variations with histological subtypes and clinicopathological parameters. Forty-one ampullary carcinomas were histologically classified into intestinal, pancreaticobiliary and unusual types. hENT1 and Ki67 expression were evaluated by immunohistochemistry, and apoptotic cells were identified by the terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate biotin nick end labelling (TUNEL) method. hENT1 overexpression was detected in 63.4% ampullary carcinomas. A significant difference in terms of hENT1 and Ki67 expression was found between intestinal vs. pancreaticobiliary types (P=0.03 and P=0.009 respectively). Moreover, a significant statistical positive correlation was found between apoptotic and proliferative Index (P=0.036), while no significant correlation was found between hENT1 and apoptosis. Our results on hENT1 expression suggest that classification of ampullary carcinoma by morphological subtypes may represent an additional tool in prospective clinical trials aimed at examining treatment efficacy; in addition, data obtained from Ki67 and TUNEL suggest a key role of hENT1 in tumour growth of ampullary carcinoma.
Collapse
Affiliation(s)
- G Perrone
- Department of Anatomical Pathology, Campus Bio-Medico University, via Alvaro del Portillo 200, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|